Skip to main content

Kairos Pharma, LTD.

KAPA
Exchange
NYSE
Industry
Pharmaceutical Preparations
SEC CIK
0001962011

No open-market purchases or sales by Kairos Pharma, LTD. insiders were filed in the last 90 days; 14 institutions reported holding it in 13F filings for Q2 2026, worth $371.1K in total; no superinvestor holds it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Kairos Pharma, LTD. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
0 filings
Insiders trading
0
Net value
$0
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Kairos Pharma, LTD., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Kairos Pharma, LTD.
NameTitleLast reported holdingLast filingFilings, past year
Bhowmick NeilChief Scientific Officer1,311,739Dec 30, 20251
Bae Hyun W.Director73,370Dec 23, 20251
Singhvi RahulDirector49,204Nov 26, 20251
Yu John SCEO and Chairman230,105Nov 26, 20251
Keyoung Hansoo MichaelDirector29,084Nov 26, 20251
Murali RamachandranVP of Research and Development299,529Nov 26, 20251
Samuelson DougChief Financial Officer293,039Nov 26, 20251

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Nov 25, 2024 (view filing)Nov 25Same dayMurali RamachandranVP of Research and DevelopmentPPurchase+200$1.59+$318+0.2%133.1K after
Nov 25, 2024 (view filing)Nov 223 daysSamuelson DougChief Financial OfficerPPurchase+2.50K$1.50+$3.75K+4.3%60.8K after
Nov 21, 2024 (view filing)Nov 201 dayYu John SCEO and ChairmanPPurchase+4.00K$1.44+$5.76K+0.1%5.34M after